304: Controversial brain tissue research, obesity drug sales and Novartis M&A drama
The removal of small amounts of brain tissue from desperately ill patients, done as part of a Mount Sinai research project, triggered alarm bells at the Food and Drug Administration and has raised broader questions about the scientific and ethical justification for live-brain research. Journalist and STAT contributor Katherine Eban joins \u201cThe Readout LOUD\u201d podcast to discuss the results of a two-year investigation. We also discuss Novartis\u2019 effort to acquire MorphoSys, and the latest news on Eli Lilly and Novo Nordisk\u2019s blockbuster obesity drugs with Elaine Chen, the newest member of STAT\u2019s biotech reporting team.